Probiotic *Streptococcus salivarius* K12 Alleviates Radiation-Induced Oral Mucositis in Mice

Yan Wang¹, Jiatong Li², Haonan Zhang², Xin Zheng², Jiantao Wang³, Xiaoyue Jia¹, Xian Peng², Qian Xie⁵, Jing Zou¹, Liwei Zheng¹, Jiyao Li², Xuedong Zhou² and Xin Xu²,6*

¹ State Key Laboratory of Oral Diseases & National Clinical Research Center for Oral Diseases & Department of Pediatric Dentistry, West China Hospital of Stomatology, Sichuan University, Chengdu, China, ² State Key Laboratory of Oral Diseases & National Clinical Research Center for Oral Diseases & Department of Endodontics, West China Hospital of Stomatology, Sichuan University, Chengdu, China, ³ State Key Laboratory of Biotherapy, Department of Lung Cancer Center and Department of Radiation Oncology, West China Hospital, Sichuan University, Chengdu, China, ⁴ State Key Laboratory of Oral Diseases & National Clinical Research Center for Oral Diseases, West China Hospital of Stomatology, Sichuan University, Chengdu, China, ⁵ Department of Endodontics, College of Dentistry, University of Illinois at Chicago, Chicago, IL, United States, ⁶ Clinical Research Center for Oral Diseases of Sichuan Province, Chengdu, China

**Background:** Oral mucositis is the most common oral complication of cancer patients receiving radiotherapy and/or chemotherapy, leading to poor quality of life. Limitations of the current interventions on radiation-induced oral mucositis (RIOM) urge the development of novel therapeutics. Here, we evaluated the treatment outcome of probiotic *Streptococcus salivarius* K12 on RIOM mice, and oral microbiota that is associated with the progress of RIOM was further investigated.

**Methods:** An experimental RIOM mouse model was established, and *S. salivarius* K12 was applied to the mouse oral cavity daily. Histological analyses were performed to evaluate the severity of oral mucositis and the treatment outcome of *S. salivarius* K12. The oral microbiota of mice was further analyzed by 16S rRNA sequencing, microbial culture and qPCR.

**Results:** Irradiation induced conspicuous mucositis in the oral cavity of mice. *S. salivarius* K12 treatment was beneficial for the healing of RIOM, as reflected by reduced ulcer size, increased basal layer epithelial cellularity and mucosal thickness, and elevated epithelial proliferation and attenuated apoptosis. RIOM mice presented significant oral microbial dysbiosis, with an overgrowth of oral anaerobes. *S. salivarius* K12 treatment reconstituted the oral microbiota and decreased the abundance of oral anaerobes of RIOM mice. In addition, *S. salivarius* K12 treatment inhibited Ni1060 in *Pasteurella* genus and downregulated the expression of nitrate reductase.

**Conclusions:** *S. salivarius* K12 treatment can alleviate RIOM and reconstituted the dysbiotic oral microbiota in mice. *S. salivarius* K12 may represent a promising adjuvant treatment to improve the quality of life of cancer patients receiving radiotherapy.

**Keywords:** *Streptococcus salivarius* K12, radiotherapy, oral mucositis, dysbiosis, probiotics
INTRODUCTION

Oral mucositis, characterized by inflammation and mucosal damage of oral mucosa, is the most common oral complication of cancer patients receiving radiotherapy and/or chemotherapy. The incidence of oral mucositis is almost 100% in head and neck cancer patients receiving radiotherapy (1, 2). 85% of patients receiving intensive chemotherapy for hematopoietic stem cell transplant also develop oral mucositis (3). Oral mucositis induced by radiotherapy/chemotherapy can cause pain, dysphagia and malnutrition, seriously affecting the quality of life of patients and interrupting anti-cancer treatment. Till now, the management of oral mucositis is still challenging. Interventions include growth factors, antibiotics, chlorhexidine, cryotherapy, low-level laser therapy and anti-inflammatory agents, but with limited efficacy (4). At present, only keratinocyte growth factor-1 (palifermin) has been approved by the US Food and Drug Administration to mitigate oral mucositis in a very limited segment of the at-risk population (5). Hence, there is still a need for the development of novel therapeutics for the better management of oral mucositis.

The pathogenesis of mucositis induced by radiotherapy/chemotherapy has been suggested in previous studies (6, 7). Sonis et al. depicted the development of oral mucositis and intestine mucositis as a dynamic process including five stages: initiation, primary damage response, signal amplification, ulceration and healing (6). Recent studies have suggested the role of oral microbiota in the development and progression of oral mucositis (8). Microbial dysbiosis, invasion and colonization of oral mucosa were involved in the pathophysiology of oral mucositis (9, 10). Pathogens contributed to the development of oral mucositis by activating inflammatory responses through pathogen-associated molecular patterns (PAMPs), which bind to pattern recognition receptors (PRRs), subsequently activate NF-κB and induce the release of pro-inflammatory cytokines (10).

Probiotics which consist of beneficial viable bacteria and bacterial components, have shown various beneficial effects on human health, particularly via modulating the disease-related dysbiotic microbiota (11, 12). Streptococcus salivarius is a commensal bacterium in the oral cavity, and the S. salivarius K12 strain that was originally isolated from the oral cavity of a healthy child, has been well recognized as an oral probiotic being used for the treatment of multiple oropharyngeal pathogen-related diseases including oral candidiasis, pharyngitis, and halitosis (13–15). S. salivarius K12 has a regulatory effect on oral microflora (15, 16), likely due to its potent production of bacteriocin-like inhibitory substances (BLISs) including Lanibiotics salivaricin A and salivaricin B. The production of BLISs contributes to the competitiveness of S. salivarius K12 over pathogens and thus benefits the oropharyngeal health (17). The regulatory effects of S. salivarius K12 on oral microbiota imply its potential use in the treatment of RIOM. Hence, we hypothesize that radiation can alter oral microbiota and predispose the host to oral mucositis, and S. salivarius K12 can alleviate mucositis by modulating the oral microbiota. To validate this hypothesis, we established a RIOM mouse model, and analyzed the ecological impact of radiation on the oral microbiota. In addition, beneficial effects of S. salivarius K12 on the healing of oral mucositis were further evaluated.

MATERIALS AND METHODS

Radiation-Induced Oral Mucositis Mouse Model

Seven-week-old male BLAB/c mice were purchased and housed under specific pathogen-free conditions. All animal procedures in this study were approved by Ethics Committee of State Key Laboratory of Oral Diseases, Sichuan University, Chengdu, China. This study conforms to the “Animal Research: Reporting of In Vivo Experiments” guidelines for preclinical studies.

After one week of environment acclimation, the mice were randomly divided into three groups (N=11 per group, 5 for macroscopic analyses and 6 for histological analyses and microbial analyses): irradiation-free (control), irradiation+Saline (IR+Saline) and irradiation+ S. salivarius K12 (IR+K12). The mice were immobilized for irradiation with chloral hydrate. The technique and set-up for head-only radiation treatment in mice were modified based on previously published studies (18). Custom-made lead shields were used for mice to limit the radiation to the heads. Mice received a high dose, single fractionated 28Gy X-ray radiation directly to their head region at rate of 3.5 Gy/min. Except for the control group, the mice received X-ray radiation. Post-irradiation mice recovered on heated pad before return to vivarium.

Treatment With Probiotics

Probiotics solution was prepared by dissolving probiotics tablets, which contain 1×10^{10} CFU of viable bacteria per tablet according to the manufacturer’s instruction (NOW Foods, USA), in sterilized saline to a concentration of 1X10^{10} CFU/ml of S. salivarius K12. 100 μl probiotic solution (1×10^{9} CFU of S. salivarius K12 per day) was applied to the oral cavity of mouse using a micropipette from day -3 to day 8. After administration, food and water were unavailable within the next 30 min to keep the probiotics in mouth as long as possible. The mice in IR+Saline group were treated with saline as placebo. All mice were sacrificed at day 9. The microbial samples were taken before sacrifice.

Macroscopic and Histological Analyses

Mice were sacrificed and the whole tongue was then removed from oral cavity. Excised tongues were stained with 0.05% toluidine blue to visualize the ulceration (19). Excised tongues of mice were stained with 0.05% toluidine blue for 10 min and rinsed with 10% acetic acid for 1 min to visualize the ulceration (19). Ulcers were visible as a deep blue color after staining. Then, the percentages of stained area to whole area of tongue surfaces were measured by pixels on Image J software to determine the ulcer area.
Paraffin sections were prepared for histological analyses. For staining based on hematoxylin and eosin (H&E), cell proliferation (PCNA), or apoptotic cells (TUNEL), specimens were fixed in 4% paraformaldehyde and embedded in paraffin. After deparaffination, sections were stained with hematoxylin and eosin to confirm the histologic changes. To measure the epithelial thickness, two sites in five randomly chosen hematoxylin and eosin-stained sections (six specimens/group) were measured. The basal layer cellularity was measured by counting the absolute number of cells at basal layer at the area of interest in five randomly chosen sections (six specimens/group). To confirm the tissue-regenerative activity (cell proliferation) of damaged tissues, sections were stained with rat monoclonal anti-mouse PCNA (1:100; Abcam, Cambridge, UK). For the apoptosis assay, TUNEL (terminal deoxynucleotidyl transferase dUTP nick end labeling) staining was performed with a TUNEL kit (Beyotime, China) according to manufacturer’s protocol to detect apoptotic cells. Slides were mounted with coverslips using DAPI Fluoromount-G (Southern Biotech, China). To quantify of cell proliferation (PCNA) and apoptotic activities, the absolute number of positive cells at the area of interest in five randomly chosen sections (six specimens/group) were counted.

Quantitative Real-Time PCR
The qPCR amplification was performed on a StepOnePlus™ Real-Time PCR System (Applied Biosystems). For quantification of total bacterial load, the reaction mixture (25 µl) contained SYBR® Premix Ex Tag II (Takara Bio), microbial genomic DNA (2 µl), and forward and reverse primers (10 µM each). Threshold cycle (CT) values were determined, and relative ratio of 16S and 18S was calculated based on the 2−ΔΔCT method (24). NI1060 was quantified with the protocol described previously (25). For quantification of the expression level of napA, microbial RNA was extracted with Trizol Reagent (Invitrogen) according to the manufacturer’s instructions. Reverse transcription of RNA into cDNA was performed with the PrimeScript RT Reagent Kit with gDNA Eraser (Takara Bio). The expression levels of napA were measured with that of the control group as control. The sequence of the primers (16S, 18S and napA) used referred to the previous study (24).

Anaerobic Bacteria Cultivation
Oral mucosa of mice was swabbed for 30 s and the swabs were then inserted into Eppendorf tubes containing 100 µL of Wilkins-Chalgren medium (Oxoid). The samples were serially diluted and plated on blood agar for two days under anaerobic conditions at 37°C. Colonies were enumerated to determine the colony-forming units (CFUs) of total cultivatable oral anaerobic bacteria (24).

Statistical Analysis
For 16S rRNA sequencing data, statistical analyses were performed with I-Sangers online tools (http://www.i-sanger.com/) (25, 26). The differences in beta diversity (revealed by PCoA) within groups were compared; the alpha diversity data and genus-level microbial composition data were analyzed by Wilcoxon rank-sum test for two group comparison and Kruskal-Wallis H test with the Dunn’s test for three group comparisons. All other data were statistically analyzed by GraphPad Prism 6. Differences between groups were analyzed by one-way analysis of variance test followed by Tukey’s test. A two-tailed P<0.05 was considered significant.

RESULTS
S. salivarius K12 Ameliorates Radiation-Induced Oral Mucositis in Mice
The body weights of mice that received irradiation decreased sharply, while S. salivarius K12 treatment alleviated the body weight loss (Figure 1A). The total body weight loss of S. salivarius K12 treatment group (~8.33g) was significantly less than that of irradiated mice (~12.05g) on the 9th day after irradiation (Figure 1B). In the oral cavity of irradiated mice, conspicuous mucositis, particularly on the lingual mucosa was observed as reflected by toluidine blue staining (Figure 1C). Topical application of S. salivarius K12 significantly reduced the severity of oral mucositis in irradiated mice (Figure 1C-E). Specifically, the relative area of mucositis including ulcers was...
significant reduced in the IR+K12 group (9.03%) as compared to that in the IR+Saline group (77.42%) (Figure 1D). The relative ulcer area in tongues of the S. salivarius K12-treated mice (5.02%) was also significantly lower than the IR+Saline group (20.21%) (Figure 1E). H&E staining showed conspicuous mucosal hypoplasia and ulceration in the tongue of irradiated mice, while S. salivarius K12 treatment partially restored the integrity of the lingual mucosa (Figure 2A). Topical use of S. salivarius K12 also significantly increased mucosal thickness (Figures 2B, C) and basal layer epithelial cellularity in both ventral and dorsal tongues (Figures 2D, E).

Further immunohistology showed that irradiation attenuated the proliferation of basal layer epithelial cells and induced significant apoptosis in both ventral and dorsal tongue of RIOM mice as compared to the irradiation-free controls (Figure 3). S. salivarius K12 treatment significantly rescued this pathology, as increased number of PCNA+ proliferative cells (Figures 3A–C) and decreased number of TUNEL+ apoptotic cells (Figures 3D–F) were observed in both dorsal and ventral tongues of the IR+K12 group compared to the IR+Saline group.

**S. salivarius K12 Modulates Oral Microbiota in RIOM Mice**

16S rRNA sequencing data showed that the oral cavity of RIOM mice harbored a microbiota with lower alpha diversity relative to the irradiation-free controls (Figure 4A). Principal coordinates analysis (PCoA) based on Bray-Curtis distance showed that the oral microbiota of RIOM was distinct from that of irradiation-free controls (Figure 4B), indicating an altered microbial structure. Further analysis of the top 15 abundant bacterial taxa revealed genus-level differences between RIOM mice and irradiation-free controls (Figure 4C). The oral microbiota of RIOM mice had significantly increased abundance of unclassified_f_Pasteurellaceae, Pasteurella, Muribacter, Corynebacterium and unclassified_O_Lactobacillales and lower levels of norank_f_Bacteroidales_S24-7_group, Rhodococcus, norank_c_Cyanobacteria, Lactobacillus, Lachnospiraceae_NK4A136_group and Escherichia-Shigella as compared to the irradiation-free controls.

The oral microbiota of RIOM mice with/without S. salivarius K12 treatment showed no difference in alpha diversity (Figure 4A). PCoA based on Bray-Curtis distance revealed differential clustering of the oral microbiota among the IR+Saline, IR+K12, and irradiation-free controls, suggesting partial reconstitution of microbial structure after S. salivarius K12 treatment (Figure 4B). More importantly, S. salivarius K12 treatment altered the microbial composition of RIOM mice. An enrichment of Pasteurella was observed in IR+Saline group as compared to the irradiation-free controls, and S. salivarius K12 treatment reduced the amount of Pasteurella in the RIOM mice (Figure 4C). Further species-specific qPCR analysis showed that a periodontitis-associated pathogen N11060 in the
Pasteurella genus was significantly enriched in IR+Saline group, and S. salivarius K12 treatment significantly reduced its abundance in the oral cavity of RIOM mice (Figure 4D).

**S. salivarius K12 Suppresses the Overgrowth of Oral Anaerobes in RIOM Mice**

Microbial samples from the oral swabs were further analyzed to investigate the effect of S. salivarius K12 treatment on the oral microbiota of RIOM mice. The oral cavity of IR+Saline group was colonized with twice the number of bacteria as compared to the irradiation-free controls; while S. salivarius K12 treatment significantly reduced the overall microbial load (Figure 5A). More importantly, the IR+Saline group presented an increased amount of cultivated anaerobic bacteria as compared to the irradiation-free controls, and S. salivarius K12 treatment significantly reduced the amount of cultivated anaerobic bacteria in RIOM mice (Figure 5B). Consistently, an elevated expression of gene encoding nitrate reductase (napA) was observed in the oral microbiota of RIOM mice as compared to that of irradiation-free controls, and S. salivarius K12 treatment significantly downregulated napA expression (Figure 5C).

**DISCUSSION**

Radiotherapy is one of the most commonly used treatment modalities for head and neck cancers, but with frequent complications as oral mucositis. Limited evidence has suggested the involvement of oral microbes in the development of oral mucositis in this context (8, 27, 28). In the current study, we demonstrated that radiation caused oral microbial dysbiosis of RIOM mice. More importantly, topical use of probiotic S. salivarius K12 ameliorated oral mucositis in RIOM mice by modulating the oral microbiota, representing a promising approach to the management of RIOM.

The pathogenesis of radiation-induced oral mucositis remains undefined, and the complex interaction between microbiota and host has been suggested (9, 10, 29). Recently, increasing evidence suggests that microbiota has played an important role in the pathogenesis of mucositis (29, 30). Hu et al. analyzed the supragingival plaque of eight nasopharyngeal carcinoma (NPC) patients receiving head and neck radiotherapy and found that the relative abundance of core microorganisms changed dynamically during radiotherapy (27, 28). Zhu et al. revealed that bacterial community structure altered progressively in NPC patients during radiotherapy, accompanied with a marked increase of certain Gram-negative bacteria. Patients who eventually developed severe oral mucositis harbored a higher abundance of Actinobacillus during the phase of erythema-patchy mucositis (8). Reyes-Gibby et al. found that changes in the abundance of genera, including 1) *Cardiobacterium* and *Granulicatella* at the baseline; 2) *Prevotella*, *Fusobacterium* and *Streptococcus* immediately before the development of oral mucositis; and 3) *Megasphaera* and *Cardiobacterium* immediately before the development of severe oral mucositis, over the course of treatment in the patients with squamous cell carcinoma of the head and neck were associated with the onset of severe oral mucositis (31). These data suggest the involvement oral microbial dysbiosis in the development of RIOM.

*S. salivarius* K12 was first isolated from the throat of a healthy child, and is currently used as a probiotic for the treatment oral malodor, oral candidiasis, secretory otitis media and pharyngotonsillitis (14, 15, 32–35). Given the presence of oral microbial dysbiosis after irradiation, we used *S. salivarius* K12 to treat the RIOM mice. Our results showed that *S. salivarius* K12 could modulate oral microbiota, and effectively alleviated RIOM, as reflected by a significant reduction of ulceration, increased
thickness of tongue mucosa and the density of basal cells, enhanced basal cell proliferation, and attenuated apoptosis. Although few studies have demonstrated beneficial effects of probiotics in the treatment/prevention of oral mucositis, satisfactory outcomes have also been reported by others using probiotics to treat intestinal mucositis induced by radiotherapy/chemotherapy. Kato et al. found that *Bifidobacterium bifidum* G9-1 could improve the microbial dysbiosis and thus ameliorated 5-Fluorouracil-induced intestinal mucositis in mice (11). Consistently, another study found that *Bifidobacterium breve* DM8310, *Lactobacillus acidophilus* DM8302, *Lactobacillus casei* DM8121 and *S. thermophiles* DM8309, ameliorated 5-Fluorouracil-induced intestinal mucositis via the reestablishment of microbial homeostasis and regulation of the TLR2/TLR4 signaling pathway (36). *Lactobacillus rhamnosus* GG also shows a protective effect on the intestinal epithelium from radiation injury, possibly through the release of lipoteichoic acid that activates the radioprotective TLR2 (37).

In addition to the shift of oral microbiota after irradiation, we also observed an increased microbial load and overgrowth of anaerobic bacteria in the oral cavity of RIOM mice, along with an elevated expression of nitrate reductase gene (*napA*). Consistently, Kato et al. reported an elevated amount of anaerobic bacteria in mice with 5-fluorouracil-induced intestinal mucositis (11). Nassar et al. also reported a higher expression levels of *napA* in Gas6−/− mice, which harbored dysbiotic microbiota with expansion of anaerobic bacteria (24). NapA, as an important nitrate reductase, plays an important role in the growth of anaerobic pathogenic bacteria. By expressing nitrate reductase, the anaerobic bacteria can use electron acceptors generated as a byproduct of inflammation to support their growth by anaerobic respiration (24, 38). Lipopolysaccharides (LPS) produced by Gram-negative anaerobes could induce inflammatory responses by activating toll-like receptor 4 signaling pathway (39), which may contribute...
to the development of oral mucositis. In the current study, *S. salivarius* K12 treatment reduced the number of anaerobic bacteria and downregulated the expression of napA in RIOM mice. In addition, *S. salivarius* K12 treatment reduced the abundance of bacterial genera including *Pasteurella*, *Corynebacterium*, *Porphyromonas*, and *Staphylococcus*. Intriguingly, an increase of NI1060 in the *Pasteurella* genus was observed in RIOM mice. NI1060 is an inflammation-related bacterium identified in murine ligature-induce periodontitis (40). The genomic sequencing of NI1060 revealed its possible virulence genes involved in lipoooligosaccharide synthesis, adhesins and bacteriotoxic proteins, which were potentially important for host adaption and induction of dysbiosis through bacterial competition and pathogenicity (41). Our recent study on periodontitis also suggests the involvement of this bacteria in periodontitis (25). The enrichment of NI1060 in the oral cavity of mice receiving radiation suggests a possible involvement of this pathogenic bacteria in the development of RIOM. Although more studies are still needed, this bacterium may provide a potential target for the treatment/prevention of RIOM.

Some cautions should be taken when interpreting data from the current study. Firstly, the RIOM mouse model was established using a single high-dose irradiation referring to a previous study (18).
Nevertheless, conventional radiotherapy for cancer patients consists of low fractionated X-ray doses lasting for weeks in most cases (42). Since single high-dose irradiation and low-dose fractionated irradiation could exert different effects on oral mucosa and oral microbiota, future studies using animal models closer to the clinical radiation regimens are warranted. Secondly, we only sampled oral microbial samples on day 9 post irradiation because overt ulceration in mouse tongue mucosa peaked 9 days after irradiation. Whether S. salivarius K12 can accelerate the restoration of microbial dysbiosis still needs dynamic sampling after irradiation. Thirdly, although S. salivarius K12 showed effectiveness in the treatment of RIOM and the inhibition of oral anaerobes in the current study, whether this probiotic strain can directly act on tissue inflammation other than competing oral anaerobes to promote the healing of RIOM still needs further investigations. It should be noted that changes in commensal bacteria took place at the early stage of radiotherapy (27, 28), suggesting that microbial alteration could possibly be an initiating factor rather than a consequence of oral mucositis. A recent systematical review including five clinical studies of 435 patients has indicated that probiotics may help reduce the incidence and mitigate the severity of cancer therapy-induced oral mucositis (43). However, as the selection and combination of probiotics, application method and target population vary among these studies, more evidence is still needed to justify the clinical application of probiotic in this scenario. In addition, the differed host responses of probiotics warrant customized probiotic interventions on patients receiving varying anti-cancer treatment modalities (44). It is also noteworthy that the use of probiotics may cause invasive infection in patients with compromised immunity (45). More work is still needed to translate the application of probiotics to the management of RIOM in the future.

In summary, our data show that probiotic S. salivarius K12 can modulate oral microbiota and ameliorate radiation-induced oral mucositis in a RIOM mice model. S. salivarius K12 as a probiotic represents a promising therapeutic against RIOM. Since probiotics have been proposed as a potential approach to the management of radiotherapy/chemotherapy-induced mucositis (46), S. salivarius K12 as an oral probiotic represents a promising adjuvant treatment to improve the quality of life of cancer-patients receiving radiotherapy.

**REFERENCES**

1. Maria OM, Eliopoulos N and Muanza T. Radiation-Induced Oral Mucositis. *Front Oncol* (2017) 7:89. doi: 10.3389/fonc.2017.00089

2. Vera-Llonch M, Oster G, Hagiwara M and Sonis S. Oral Mucositis in Patients Undergoing Radiation Treatment for Head and Neck Carcinoma. *Cancer* (2006) 106(2):329–36. doi: 10.1002/cncr.21622

3. Chaudhry HM, Bruce AJ, Wolf RC, Litzow MR, Hogan WJ, Patnaik MS, et al. The Incidence and Severity of Oral Mucositis Among Allogeneic Hematopoietic Stem Cell Transplantation Patients: A Systematic Review. *Biol Blood Marrow Transplant* (2016) 22(4):605–16. doi: 10.1016/j.bbmt.2015.09.014

4. Hong CHL, Gueiros LA, Fulton JS, Cheng KKF, Kandwal A, Galiti D, et al. Systematic Review of Basic Oral Care for the Management of Oral Mucositis in Cancer Patients and Clinical Practice Guidelines. *Support Care Cancer* (2019) 27(10):3949–67. doi: 10.1007/s00520-019-04848-4

5. Cinausero M, Aprile G, Ermacora P, Basile D, Vitale MG, Fanotto V, et al. New Frontiers in the Pathobiology and Treatment of Cancer Regimen-Related Mucosal Injury. *Front Pharmacol* (2017) 8:354. doi: 10.3389/fphar.2017.00354

6. Sonis ST. The Pathobiology of Mucositis. *Nat Rev Cancer* (2004) 4(4):277–84. doi: 10.1038/nrc1318

7. Vanhoecke B, De Ryck T, Stringer A, Van de Wiele T and Keefe D. Microbiota and Their Role in the Pathogenesis of Oral Mucositis. *Oral Dis* (2014) 21(1):17–30. doi: 10.1111/odi.12224

8. Zhu XX, Yang XJ, Chao YL, Zheng HM, Sheng HF, Liu HY, et al. The Potential Effect of Oral Microbiota in the Prediction of Mucositis During Radiotherapy for Nasopharyngeal Carcinoma. *EBioMedicine* (2017) 18:23–31. doi: 10.1016/j.ebiom.2017.02.002

9. Sonis ST. The Chicken or the Egg? Changes in Oral Microbiota as Cause or Consequence of Mucositis During Radiation Therapy. *EBioMedicine* (2017) 18:7–8. doi: 10.1016/j.ebiom.2017.03.017

**DATA AVAILABILITY STATEMENT**

The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found below: https://www.ncbi.nlm.nih.gov/, SRP276563.

**ETHICS STATEMENT**

The animal study was reviewed and approved by Ethics Committee of State Key Laboratory of Oral Diseases, Sichuan University, Chengdu, China.

**AUTHOR CONTRIBUTIONS**

YW, JTL, XIZ and XX contributed to conception, design, data acquisition, analysis, and interpretation, drafted and critically revised the manuscript. HZ, XuZ and JW contributed to data acquisition and interpretation, critically revised the manuscript. XJ, XP, JZ, LZ and JYL contributed to data interpretation, critically revised the manuscript. All authors contributed to the article and approved the submitted version.

**FUNDING**

This study was supported by the National Natural Science Foundation of China (81600864, 81771099), and a research grant from the Science and Technology Department of Sichuan Province (2018SZ0121).

**ACKNOWLEDGMENTS**

We thank Dr. Ruizhan Tong in helping with establishing the radiation-induced oral mucositis mouse model.
10. Vanhoecke BW, De Ryck TR, De boel K, Wiles S, Boterberg T, Van de Wiele T, et al. Low-Dose Irradiation Affects the Functional Behavior of Oral Microbiota in the Context of Mucositis. *Exp Biol Med (Maywood)* (2016) 241(1):60–70. doi: 10.1177/1535370215599546

11. Kato S, Hamouda N, Kano Y, Okawa Y, Tanaka Y, Matsumoto K, et al. Probiotic Bifidobacterium Bifidum G9-1 Attenuates 5-Fluorouracil-Induced Intestinal Mucositis in Mice Via Suppression of Dysbiosis-Related Secondary Inflammatory Responses. *Clin Exp Pharmacol Physiol* (2017) 44(10):1017–25. doi: 10.1111/1440-1681.12792

12. Panebianco C, Latiano T and Piazzena V. Microbiota Manipulation by Probiotic Administration as Emerging Tool in Cancer Prevention and Therapy. *Front Oncol* (2020) 10:6679. doi: 10.3389/fonc.2020.200679

13. Burton JP, Chilcott CN, Moore CJ, Speiser G, Tagg JR. A Preliminary Study of the Effect of Probiotic Streptococcus Salivarius K12 on Oral Malodour Parameters. *J Appl Microbiol* (2006) 100(4):754–64. doi: 10.1111/j.1365-2762.2006.02837.x

14. Di Pierro F, Adami T, Rapacioli G, Giardini N, Streitberger C. Clinical Evaluation of the Oral Probiotic Streptococcus Salivarius K12 in the Prevention of Recurrent Pharyngitis and/or Tonsillitis Caused by Streptococcus Pyogenes in Adults. *Expert Opin Biol Ther* (2013) 13(3):339–43. doi: 10.1517/14712598.2013.7358711

15. Masdea L, Kulik EM, Hauser-Gerspach I, Ramseier AM, Filippi A and Panebianco C, Latiano T and Pazienza V. Microbiota Manipulation by Probiotic Administration as Emerging Tool in Cancer Prevention and Therapy. *Front Oncol* (2020) 10:6679. doi: 10.3389/fonc.2020.200679

16. T I, Sumita Y, Minamizato T, Umebayashi M, Liu Y, Tran SD, et al. Bone Chemosensory Cells Are Immune Sentinels for Periodontitis. *Front Immunol* (2020) 12:705. doi: 10.3389/fimmu.2020.00774

17. Winter SE and Bäumler AJ. Dysbiosis in the Inflammatory Response of Human Epithelial Cells and Promotes Host-Microbe Homeostasis. *Infect Immun* (2008) 76(9):4163–75. doi: 10.1128/iai.00188-08

18. Welcombe PA, Hale JD, Heng NC and Tagg JR. Developing Oral Probiotics From Streptococcus Salivarius. *Future Microbiol* (2012) 7(12):1355–71. doi: 10.2217/fmb.12.113

19. Di Pierro F, Tizzano M, Redding K, He J, Peng X, Jiang P, et al. Gingival Solitary Dynamic Core Microbiome of Plaque Microbiota During Head-and-Neck Radiotherapy Using Pyrosequencing. *PloS One* (2013) 8(2):e56343. doi: 10.1371/journal.pone.0056343

20. Vasconcelos RM, Sanfilippo N, Paster BJ, Kerr AR, Li Y, Ramalho L, et al. Host-Microbiome Cross-talk in Oral Mucositis. *J Dent Res* (2016) 95(7):725–33. doi: 10.1177/002203451661890

21. Wang Y, Zhou X, Xu X. Oral Microbiota: An Overlooked Etiology for Chemotherapy-Induced Oral Mucositis? *J Formos Med Assoc* (2015) 114:297–9. doi: 10.1016/j.jfma.2013.10.014

22. Reyes-Gibby CC, Wang J, Zhang L, Peterson CB, Do KA, Jeng RR, et al. Oral Microbiome and Onset of Oral Mucositis in Patients With Squamous Cell Carcinoma of the Head and Neck. *Cancer* (2020) 126(23):5124–36. doi: 10.1002/cncr.33161

23. Gregori G, Righi O, Risso P, Boiard G, Demuru G, Ferretti A, et al. Reduction of Group A Beta-Hemolytic Streptococcus Pharyngo-Tonsillar Infections Associated With Use of the Oral Probiotic Streptococcus Salivarius K12: A Retrospective Observational Study. *Ther Clin Risk Manag* (2016) 12:87–92. doi: 10.2147/tcrm.s96134

24. Nassar M, Tabib Y, Capucha T, Mizraji G, Nir T, Pevsner-Fischer M, et al. Effect of Streptococcus Salivarius K12 on the In Vitro Growth of Candida Albicans and its Protective Effect in an Oral Candidiasis Model. *Appl Environ Microbiol* (2012) 78(7):2190–9. doi: 10.1128/aem.07055-11

25. Jamali Z, Aminabadi NA, Samie M, Sighari Deljavan A, Shokravi M and Shirazi S. Impact of Chlorhexidine Pretreatment Followed by Probiotic Streptococcus Salivarius Strain K12 on Halitosis in Children: A Randomised Controlled Clinical Trial. *Oral Health Prev Dent* (2016) 14(4):305–13. doi: 10.3290/j.ohpd.a36521

26. Tang Y, Wu Y, Huang Z, Dong W, Deng Y, Wang F, et al. Administration of Probiotic Mixture DM1 Ameliorated 5-Fluorouracil-Induced Intestinal Mucositis and Dysbiosis in Rats. *Nutrition* (2017) 33:96–104. doi: 10.1016/j.nut.2016.05.003

27. Riehl TE, Alvarado D, Ee X, Zuckerman A, Foster L, Kapoor V, et al. Lactobacillus Rhamnosus GG Protects the Intestinal Epithelium From Radiation Injury Through Release of Lipoteichoic Acid, Macrophage Activation and the Migration of Mesenchymal Stem Cells. *Gut* (2019) 68 (6):1003–13. doi: 10.1136/gutjnl-2018-316226

28. Winter SE and Bäumler AJ. Dysbiosis in the Inflamed Intestine: Chance Favors the Prepared Microbe. *Gut Microbes* (2014) 5(1):71–3. doi: 10.4161/gmic.27129

29. Doyle SL and O’Neill LA. Toll-Like Receptors: From the Discovery of NFκBp65 to New Insights Into Transcriptional Regulations in Inflamed Intestine. *Biochem Pharmacol* (2006) 72(9):1102–13. doi: 10.1016/j.bcp.2006.07.010

30. Jiao Y, Darzi Y, Tawaratsumida K, Marchesan JT, Hasegawa M, Moon H, et al. Induction of Bone Loss by Pathobiont-mediated Nod1 Signaling in the Oral Cavity. *Cell Host Microbe* (2013) 13(5):595–601. doi: 10.1016/j.chom.2013.04.005

31. Neill LA. Toll-Like Receptors: From the Discovery of NFκBp65 to New Insights Into Transcriptional Regulations in Inflamed Intestine. *Biochem Pharmacol* (2006) 72(9):1102–13. doi: 10.1016/j.bcp.2006.07.010

32. Zmora N, Zilberman-Schapira G, Suez J, Mor J, Udi-Bachash M, Bashiri S, et al. Personalized Gut Mucosal Colonization Resistance to Empiric Cancer Therapy. *Cancer Therapy*.
Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.